Selecta Biosciences, Inc. (SELB)
SELBPrice: $0.88
Fair Value: 🔒
🔒score
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage t... more
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and d... more
Description
Shares
| Market Cap | $135.20M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Carsten Brunn |
| IPO Date | 2016-06-22 | CAGR | 0.29% |
| Employees | 64 | Website | selectabio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.11% | Total Yield | 0.11% |
SELB chart loading...
Fundamentals
Technicals
| Enterprise Value | $-129.64M | P/E Ratio | -3.04 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 5.89 | P/B Ratio | -9.06 |
| P/CF Ratio | -0.67 | P/FCF Ratio | -2.46 |
| EPS | $-0.29 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 27.03% | Gross Margin | 0.81% |
| Operating Margin | 1.23% | Profit Margin | -2.5% |
| ROE | 7.55% | ROA | -0.15% |
| ROCE | 0.08% | Current Ratio | 13.33 |
| Quick Ratio | 13.33 | Cash Ratio | 13.08 |
| Debt/Equity | -5.28 | Interest Coverage | -9.98 |
| Altman Z Score | -2.28 | Piotroski Score | 3 |